EQRX INC C/WTS (TO PUR COM) | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
EQRX INC C/WTS (TO PUR COM) | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
EQRX INC C/WTS (TO PUR COM) | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
EQRX INC C/WTS (TO PUR COM) | S-8 POS: S-8 POS
EQRX INC C/WTS (TO PUR COM) | S-8 POS: S-8 POS
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | DEFA14A: Others
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | DEFM14A: Definitive proxy statement relating to merger or acquisition
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | 8-K: EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | S-3: Registration statement for specified transactions by certain issuers
EQRX INC C/WTS (TO PUR COM) | S-3: Registration statement for specified transactions by certain issuers
EQRX INC C/WTS (TO PUR COM) | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
EQRX INC C/WTS (TO PUR COM) | 8-K: EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | 8-K: Current report
EQRX INC C/WTS (TO PUR COM) | 8-K: EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
No Data